Surrozen (SRZN) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Sutro Biopharma (STRO) over the past year, gaining 99.2% versus a gain of 74.5%. Over five years, SRZN leads with a -73.5% price change compared with -92.3% for STRO. Surrozen is the larger company by market cap ($328.7 million vs $254.0 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SRZN | STRO |
|---|---|---|
| Share price | $27.97 | $15.32 |
| Market cap | $328.75M | $254.02M |
| 1-day change | +11.23% | +4.50% |
| YTD return | +23.76% | +26.71% |
| 1-year return | +99.22% | +74.52% |
| 5-year return | -73.48% | -92.28% |
| EPS (TTM) | $-39.08 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $37.83 | $43.85 |
| 52-week low | $11.39 | $7.15 |
| Distance from 52-week high | -26.06% | -65.06% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +73.04% | +208.29% |
| Average volume | 475.02K | 286.74K |
| Shares outstanding | 11.75M | 16.58M |
| Employees | 44 | 128 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed STRO by 24.7 percentage points over the past year.
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 128 employees
SRZN vs STRO FAQ
Which is bigger, Surrozen or Sutro Biopharma?
Surrozen (SRZN) is larger, with a market capitalization of $328.75M compared with $254.02M for Sutro Biopharma (STRO).
Which stock has performed better over the past year, SRZN or STRO?
SRZN returned +99.22% over the past 12 months, compared with +74.52% for STRO (price return, excluding dividends). Past performance does not predict future results.
Are Surrozen and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.